Annual CFI
N/A
December 31, 2023
Summary
- SEEL annual cash flow from investing activities is not available.
Performance
SEEL Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFI
N/A
June 30, 2024
Summary
- SEEL quarterly cash flow from investing activities is not available.
Performance
SEEL Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFI
N/A
June 30, 2024
Summary
- SEEL TTM cash flow from investing activities is not available.
Performance
SEEL TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
SEEL Cash From Investing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | - | - | - |
3 y3 years | - | - | - |
5 y5 years | - | - | - |
SEEL Cash From Investing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | ||||||
5 y | 5-year | ||||||
alltime | all time |
Seelos Therapeutics Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
Jun 2018 | - | $0.00(0.0%) | $459.00 K(-35.3%) |
Mar 2018 | - | $0.00(-100.0%) | $709.00 K(-94.2%) |
Dec 2017 | $12.21 M(+4507.2%) | $209.00 K(-16.4%) | $12.21 M(+1.7%) |
Sep 2017 | - | $250.00 K(0.0%) | $12.00 M(+2.1%) |
Jun 2017 | - | $250.00 K(-97.8%) | $11.75 M(+0.7%) |
Mar 2017 | - | $11.50 M(>+9900.0%) | $11.67 M(+4304.2%) |
Dec 2016 | $265.00 K(-182.3%) | $3000.00(>+9900.0%) | $265.00 K(+81.5%) |
Sep 2016 | - | $0.00(-100.0%) | $146.00 K(+23.7%) |
Jun 2016 | - | $168.00 K(+78.7%) | $118.00 K(-287.3%) |
Mar 2016 | - | $94.00 K(-181.0%) | -$63.00 K(-80.4%) |
Dec 2015 | -$322.00 K(-322.1%) | -$116.00 K(+314.3%) | -$322.00 K(+12.6%) |
Sep 2015 | - | -$28.00 K(+115.4%) | -$286.00 K(-12.3%) |
Jun 2015 | - | -$13.00 K(-92.1%) | -$326.00 K(-214.4%) |
Mar 2015 | - | -$165.00 K(+106.3%) | $285.00 K(+96.6%) |
Dec 2014 | $145.00 K(-96.9%) | -$80.00 K(+17.6%) | $145.00 K(-3725.0%) |
Sep 2014 | - | -$68.00 K(-111.4%) | -$4000.00(-102.9%) |
Jun 2014 | - | $598.00 K(-296.1%) | $136.00 K(-132.0%) |
Mar 2014 | - | -$305.00 K(+33.2%) | -$425.00 K(-109.0%) |
Dec 2013 | $4.71 M(+340.9%) | -$229.00 K(-418.1%) | $4.71 M(+2.5%) |
Sep 2013 | - | $72.00 K(+94.6%) | $4.60 M(-26.0%) |
Jun 2013 | - | $37.00 K(-99.2%) | $6.21 M(+0.6%) |
Mar 2013 | - | $4.83 M(-1512.0%) | $6.18 M(+478.4%) |
Dec 2012 | $1.07 M(+210.5%) | -$342.00 K(-120.3%) | $1.07 M(-45.3%) |
Sep 2012 | - | $1.69 M(>+9900.0%) | $1.95 M(+704.5%) |
Jun 2012 | - | $2000.00(-100.7%) | $242.70 K(+237.6%) |
Mar 2012 | - | -$280.00 K(-151.6%) | $71.90 K(-79.1%) |
Dec 2011 | $344.00 K(-178.9%) | $542.50 K(-2588.5%) | $344.00 K(-218.0%) |
Sep 2011 | - | -$21.80 K(-87.1%) | -$291.60 K(-202.0%) |
Jun 2011 | - | -$168.80 K(+2036.7%) | $286.00 K(-178.9%) |
Mar 2011 | - | -$7900.00(-91.5%) | -$362.50 K(-16.9%) |
Dec 2010 | -$436.00 K(-226.6%) | -$93.10 K(-116.8%) | -$436.00 K(+26.2%) |
Sep 2010 | - | $555.80 K(-168.0%) | -$345.50 K(-61.7%) |
Jun 2010 | - | -$817.30 K(+904.1%) | -$901.30 K(-1123.0%) |
Mar 2010 | - | -$81.40 K(+3030.8%) | $88.10 K(-74.4%) |
Dec 2009 | $344.50 K(-56.7%) | -$2600.00(<-9900.0%) | $344.50 K(-18.4%) |
Sep 2009 | - | $0.00(-100.0%) | $422.10 K(+2.7%) |
Jun 2009 | - | $172.10 K(-1.7%) | $410.90 K(+74.8%) |
Mar 2009 | - | $175.00 K(+133.3%) | $235.10 K(-70.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2008 | $796.00 K(+433.9%) | $75.00 K(-769.6%) | $796.10 K(-16.9%) |
Sep 2008 | - | -$11.20 K(+202.7%) | $957.70 K(-60.6%) |
Jun 2008 | - | -$3700.00(-100.5%) | $2.43 M(+1.9%) |
Mar 2008 | - | $736.00 K(+211.1%) | $2.39 M(+1499.7%) |
Dec 2007 | $149.10 K(-137.5%) | $236.60 K(-83.8%) | $149.10 K(-83.5%) |
Sep 2007 | - | $1.46 M(-3070.9%) | $906.00 K(-294.2%) |
Jun 2007 | - | -$49.20 K(-96.7%) | -$466.50 K(-182.3%) |
Mar 2007 | - | -$1.50 M(-251.0%) | $566.70 K(-242.5%) |
Dec 2006 | -$397.80 K(-155.0%) | $993.50 K(+1013.8%) | -$397.80 K(-51.9%) |
Sep 2006 | - | $89.20 K(-90.9%) | -$826.50 K(+190.1%) |
Jun 2006 | - | $984.00 K(-139.9%) | -$284.90 K(-47.9%) |
Mar 2006 | - | -$2.46 M(-536.3%) | -$547.20 K(-175.6%) |
Dec 2005 | $723.30 K(-173.4%) | $564.80 K(-10.5%) | $723.40 K(+90.3%) |
Sep 2005 | - | $630.80 K(-12.6%) | $380.20 K(-126.5%) |
Jun 2005 | - | $721.70 K(-160.4%) | -$1.44 M(-34.3%) |
Mar 2005 | - | -$1.19 M(-638.8%) | -$2.19 M(+122.1%) |
Dec 2004 | -$985.00 K(+386.2%) | $221.60 K(-118.7%) | -$985.00 K(+289.3%) |
Sep 2004 | - | -$1.19 M(+3920.3%) | -$253.00 K(-59.5%) |
Jun 2004 | - | -$29.50 K(-431.5%) | -$624.80 K(-17.4%) |
Mar 2004 | - | $8900.00(-99.1%) | -$756.40 K(+273.3%) |
Dec 2003 | -$202.60 K(-197.9%) | $953.60 K(-161.2%) | -$202.60 K(-88.4%) |
Sep 2003 | - | -$1.56 M(+867.0%) | -$1.74 M(+173.8%) |
Jun 2003 | - | -$161.10 K(-128.6%) | -$637.30 K(-133.3%) |
Mar 2003 | - | $562.70 K(-195.6%) | $1.91 M(+825.4%) |
Dec 2002 | $206.90 K(-113.2%) | -$588.60 K(+30.7%) | $206.90 K(-91.3%) |
Sep 2002 | - | -$450.30 K(-118.8%) | $2.38 M(-22.7%) |
Jun 2002 | - | $2.39 M(-308.8%) | $3.08 M(-659.5%) |
Mar 2002 | - | -$1.15 M(-172.1%) | -$550.80 K(-65.0%) |
Dec 2001 | -$1.57 M(-86.3%) | $1.59 M(+540.4%) | -$1.57 M(-84.4%) |
Sep 2001 | - | $248.00 K(-120.0%) | -$10.07 M(-12.4%) |
Jun 2001 | - | -$1.24 M(-42.7%) | -$11.49 M(-1.1%) |
Mar 2001 | - | -$2.17 M(-68.7%) | -$11.63 M(+1.0%) |
Dec 2000 | -$11.52 M(<-9900.0%) | -$6.91 M(+489.6%) | -$11.52 M(+150.2%) |
Sep 2000 | - | -$1.17 M(-14.7%) | -$4.60 M(+34.2%) |
Jun 2000 | - | -$1.37 M(-33.2%) | -$3.43 M(+66.8%) |
Mar 2000 | - | -$2.06 M | -$2.06 M |
Dec 1999 | $100.00 K(-91.8%) | - | - |
Dec 1998 | $1.22 M(-171.1%) | - | - |
Dec 1997 | -$1.72 M | - | - |
FAQ
- What is the all time high annual CFI for Seelos Therapeutics?
- What is the all time high quarterly CFI for Seelos Therapeutics?
- What is the all time high TTM CFI for Seelos Therapeutics?
What is the all time high annual CFI for Seelos Therapeutics?
Seelos Therapeutics all-time high annual cash flow from investing activities is $12.21 M
What is the all time high quarterly CFI for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly cash flow from investing activities is $11.50 M
What is the all time high TTM CFI for Seelos Therapeutics?
Seelos Therapeutics all-time high TTM cash flow from investing activities is $12.21 M